Cardiovascular-kidney-metabolic (CKM) syndrome represents a convergence of metabolic dysfunction, chronic kidney disease, and cardiovascular disease driven by excess adipose tissue and insulin resistance. This narrative review identifies glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP receptor agonists as particularly promising interventions, delivering substantial weight loss alongside cardiovascular benefits for early-stage CKM patients. The analysis reinforces ACE inhibitors and ARBs as foundational therapy, while highlighting SGLT2 inhibitors' dual cardiovascular and kidney-protective effects. This multi-target pharmacologic approach reflects a significant evolution in treating interconnected metabolic conditions rather than addressing each separately. The emphasis on early intervention at CKM stages 1-2 suggests potential for preventing progression to advanced organ damage. However, the review's narrative format limits assessment of comparative effectiveness between interventions. The pharmacist-centric perspective, while valuable for implementation, may not fully capture the complexity of specialist coordination required. This represents confirmatory evidence supporting integrated treatment paradigms, though the lack of novel clinical data limits its immediate impact on practice guidelines.